

FINANCIAL TEAR SHEET


Corporate Profile

We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our collaborators – a novel product pipeline of central nervous system, or CNS, therapies to address areas of high unmet medical need, such as epilepsy, migraine, and pain.

Stock Performance

XENE (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$8.42
Change (%)	▲ 0.07 (0.84%)
Volume	162,473
52 Week Low	\$2.10
Market Cap	\$210,756,906
Rolling EPS	-1.80
PE Ratio	0
Shares Outstanding	25,240,348



Data as of 11/13/18 4:00 p.m. ET

Recent Press Releases & Upcoming Events

November 7, 2018 - [Xenon Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference](#)

November 6, 2018 - [Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update](#)

October 30, 2018 - [Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update](#)

Date	Title
11/13/18 9:30 a.m. ET	Xenon Pharmaceuticals at the Stifel 2018 Healthcare Conference Location New York, NY

SEC Filings

Filing Date	Form
11/06/18	10-Q
11/06/18	8-K
09/13/18	424B5
09/13/18	8-K

Corporate Governance

[Simon Pimstone, MBChB, Ph.D., FRCPC](#)

[Ian Mortimer, MBA, CPA, CMA](#)

[Ernesto Aycardi, M.D.](#)

[Robin Sherrington, Ph.D.](#)

[James Empfield, Ph.D.](#)

[Charles Cohen, PhD](#)

[Jodi Regts, BA, MBA](#)

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)